List of Excipients in Branded Drug EPCLUSA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	EPCLUSA	velpatasvir and sofosbuvir	61958-2201	ALCOHOL	2034-07-30
Gilead Sciences Inc	EPCLUSA	velpatasvir and sofosbuvir	61958-2201	CELLULOSE, MICROCRYSTALLINE	2034-07-30
Gilead Sciences Inc	EPCLUSA	velpatasvir and sofosbuvir	61958-2201	COPOVIDONE K25-31	2034-07-30
Gilead Sciences Inc	EPCLUSA	velpatasvir and sofosbuvir	61958-2201	CROSCARMELLOSE SODIUM	2034-07-30
Gilead Sciences Inc	EPCLUSA	velpatasvir and sofosbuvir	61958-2201	FERRIC OXIDE RED	2034-07-30
Gilead Sciences Inc	EPCLUSA	velpatasvir and sofosbuvir	61958-2201	MAGNESIUM STEARATE	2034-07-30

Epclusa Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

Epclusa is Gilead Sciences’ fixed-dose combination of sofosbuvir and velpatasvir for chronic hepatitis C virus infection. Its commercial value is driven by broad genotype coverage, a once-daily oral tablet, and a pediatric granule formulation. The excipient opportunity is concentrated in generic formulation development, pediatric delivery, low-cost manufacturing, supply-chain resilience, and differentiated regional presentations rather than in a new active pharmaceutical ingredient.

The principal formulation targets are dose uniformity, dissolution control, physical stability, moisture management, coating performance, and acceptable administration for children. Because Epclusa contains two potent, chemically distinct antivirals, excipient selection must support both blend uniformity and release of each active ingredient without creating food- or pH-dependent performance problems.

What is Epclusa and which formulations are commercially relevant?

Epclusa contains 400 mg of sofosbuvir and 100 mg of velpatasvir per tablet. The FDA-approved product is administered once daily, with or without food, for adults and pediatric patients weighing at least 17 kg. The product is available as a film-coated tablet and as oral pellets for certain pediatric patients.

Product attribute	Epclusa characteristic
Active ingredients	Sofosbuvir and velpatasvir
Strength	400 mg sofosbuvir / 100 mg velpatasvir
Dosage form	Film-coated tablet; oral pellets
Administration	Once daily
Food requirement	May be taken with or without food
Therapeutic area	Chronic hepatitis C
Product type	Small-molecule fixed-dose combination
Primary commercial markets	United States, Europe, high-burden hepatitis C markets, licensed generic territories
Biosimilar exposure	None; Epclusa is not a biologic

The tablet is the main commercial format. The pediatric granule or pellet presentation creates a separate opportunity because it addresses swallowing limitations, dose administration, caregiver handling, and palatability.

Which excipients are used in Epclusa tablets?

The US prescribing information identifies the principal inactive ingredients used in Epclusa tablets as copovidone, croscarmellose sodium, colloidal silicon dioxide, mannitol, microcrystalline cellulose, and magnesium stearate. The film coating contains conventional coating materials, including hypromellose, titanium dioxide, polyethylene glycol, and iron oxide colorants, according to the product labeling.[1]

Excipient class	Representative Epclusa function	Formulation risk addressed
Copovidone	Binder and dry-granulation or wet-granulation aid	Tablet strength and content uniformity
Croscarmellose sodium	Superdisintegrant	Rapid tablet breakup
Colloidal silicon dioxide	Glidant and moisture-management aid	Powder flow and blend handling
Mannitol	Diluent and mouthfeel contributor	Compressibility and tablet mass
Microcrystalline cellulose	Diluent and compression aid	Mechanical strength
Magnesium stearate	Lubricant	Ejection and tooling protection
Hypromellose	Film-forming polymer	Coating integrity
Polyethylene glycol	Plasticizer	Coating flexibility
Titanium dioxide and iron oxides	Opacifier and colorants	Product identification and light protection

The listed excipients do not necessarily establish the optimal composition for a generic product. A generic manufacturer can use different inactive ingredients if the product meets applicable quality, bioequivalence, stability, dissolution, and safety requirements.

How should a generic manufacturer design an Epclusa excipient platform?

A practical generic strategy should begin with a quality-by-design assessment of the two active ingredients rather than copying the reference formulation. The key variables are particle size, solid-state form, bulk density, electrostatic behavior, blend segregation, lubricant sensitivity, and the dissolution profile of each antiviral.

Content uniformity is the primary technical issue

Sofosbuvir and velpatasvir have different physicochemical properties and are present at a 4:1 dose ratio. A formulation that produces acceptable average assay can still fail content-uniformity testing if the actives segregate during transfer, compression, or tablet dedusting.

Commercially relevant approaches include:

• Separate premixes for each active ingredient.
• Ordered mixing using a carrier excipient.
• Granulation to reduce density and particle-size differences.
• Low-shear blending followed by controlled lubrication.
• In-process blend sampling at multiple equipment locations.
• Equipment and process controls designed to limit segregation during scale-up.

A generic developer should not assume that direct compression is the lowest-cost solution. Direct compression can reduce processing steps, but it may increase segregation risk and dependence on narrow excipient particle-size specifications.

Dissolution must be controlled for both actives

Velpatasvir has limited aqueous solubility and is sensitive to gastrointestinal pH conditions. Sofosbuvir has different dissolution and degradation behavior. The formulation must release both actives rapidly and consistently across relevant pH media.

Potential technical levers include:

• Superdisintegrant level and distribution.
• Wetting-agent selection, if permitted by the target profile.
• Particle-size reduction or controlled micronization.
• Solid-dispersion or amorphous-dispersion approaches for velpatasvir.
• Granulation strategy and granule porosity.
• Compression force and tablet hardness.
• Film-coat weight and coating uniformity.

A formulation that improves velpatasvir dissolution but slows sofosbuvir release may create a regulatory problem. The development target is a balanced dissolution profile that remains robust across manufacturing-scale variation.

Moisture and solid-state control affect shelf life

The excipient system should limit moisture uptake and chemical interaction with the active ingredients. Mannitol and microcrystalline cellulose can provide useful bulk and compression properties, but their grades, water content, and storage conditions can affect tablet performance. Colloidal silicon dioxide can improve flow, but excessive use may impair compactability or alter dissolution.

The most valuable excipient suppliers will provide narrow, controlled specifications for:

• Water content and water activity.
• Particle-size distribution.
• Bulk and tapped density.
• Degree of substitution for superdisintegrants.
• Peroxide and aldehyde impurities.
• Microbial quality.
• Elemental impurities.
• Compendial compliance and change-control history.

For a high-volume antiviral, supplier qualification and dual sourcing can be as commercially important as nominal excipient price.

What formulation patents protect Epclusa?

Epclusa’s most important exclusivity historically derives from the active ingredients and combination-product protection, not from a distinctive excipient system. Formulation developers must evaluate several patent categories:

1. Sofosbuvir compound and prodrug patents.
2. Velpatasvir compound and related antiviral patents.
3. Fixed-dose combination patents.
4. Pharmaceutical composition and dosage-form patents.
5. Method-of-treatment patents.
6. Pediatric formulation or administration patents.
7. Manufacturing-process and solid-state patents.

The FDA Orange Book is the relevant US source for patents listed against an approved drug application. FDA’s Orange Book entry should be reviewed for the current Epclusa listing, patent expiration dates, pediatric exclusivity, and any listed patent certifications.[2]

A generic applicant must distinguish between:

• A Paragraph I certification, where no patent is listed.
• A Paragraph II certification, where the patent has expired.
• A Paragraph III certification, where the applicant seeks approval after patent expiry.
• A Paragraph IV certification, where the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

Excipient substitutions can reduce infringement exposure for formulation claims, but they do not eliminate risk from active-ingredient, combination, method-of-use, or manufacturing patents. A non-infringing excipient system is therefore only one part of a freedom-to-operate strategy.

When does Epclusa lose exclusivity and when can generics launch?

Epclusa’s launch and exclusivity position depends on jurisdiction, patent-family scope, pediatric extensions, regulatory exclusivity, and settlement terms. The product launched in the United States in 2016. Patent expiry is not a single global date because sofosbuvir and velpatasvir rights differ by country and because Gilead entered voluntary licensing arrangements for selected territories.

Exclusivity element	Commercial relevance
New chemical entity exclusivity	Historically protected initial FDA approval period
Combination-product patents	May cover the fixed-dose Epclusa product
Active-ingredient patents	Can delay unrestricted generic competition
Method-of-use patents	May affect labeling and carve-out strategy
Pediatric exclusivity	Can extend certain US regulatory protections
Patent settlements	May create negotiated generic-entry dates
Voluntary licenses	Permit generic supply in defined countries before global patent expiry

The first generic launch date is usually determined by the earliest legally available entry route, not by the last patent expiry in the portfolio. A first Paragraph IV filer may receive 180-day exclusivity if it satisfies the statutory requirements and no forfeiture event applies. Later applicants may enter under different conditions if the first filer’s exclusivity is forfeited or if a settlement permits multiple launches.

Because the exact launch date depends on current Orange Book data, court orders, certifications, and settlement agreements, commercial forecasts should use scenario dates rather than a single global expiry assumption.

Which companies are challenging or competing with Epclusa?

Competition occurs at three levels: branded direct-acting antivirals, authorized or licensed generics, and independent generic manufacturers.

Branded competition

Epclusa competes with other direct-acting antiviral regimens, including:

• Mavyret, a glecaprevir/pibrentasvir product from AbbVie.
• Vosevi, a sofosbuvir/velpatasvir/voxilaprevir product from Gilead.
• Harvoni, a ledipasvir/sofosbuvir product from Gilead, where still commercially relevant.
• Regional generic combinations containing sofosbuvir, velpatasvir, or alternative HCV agents.

Mavyret is the most important branded comparator in many treatment settings because it offers broad genotype coverage and a shorter treatment course for certain patient groups. Vosevi competes primarily in retreatment and resistance-related settings rather than as a direct substitute for every Epclusa prescription.

Generic and licensed competition

Gilead’s voluntary licensing and generic partnerships have enabled access to sofosbuvir- and velpatasvir-based products in selected low- and middle-income countries. The Medicines Patent Pool has described licensing arrangements involving Gilead HCV products, including access to generic manufacturing in defined territories.[3]

This creates a split market:

• In licensed countries, price and supply reliability are central.
• In non-licensed or higher-income countries, patent litigation and regulatory approval are more important.
• In public-health tenders, excipient cost, batch reliability, packaging, and stability under difficult storage conditions directly affect contract awards.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not a novel excipient sold as a premium ingredient. It is a validated, reliable formulation platform that reduces manufacturing risk and supports regulatory filing.

High-value excipient opportunities

Direct-compression systems

A co-processed mannitol-cellulose or cellulose-silica system could improve flow, compressibility, and blend uniformity while reducing the number of processing steps. The commercial value depends on demonstrated performance with both active ingredients and on a clear regulatory package.

Low-moisture excipient systems

Suppliers can target grades with controlled water activity and low reactive impurity profiles. This is relevant where stability data show sensitivity to moisture, heat, or excipient-related degradation products.

Pediatric granule platforms

Pediatric formulations offer the strongest product-differentiation opportunity. Useful technologies include:

• Taste-masked multiparticulates.
• Sprinkle granules.
• Low-dust sachet systems.
• Unit-dose stick packs.
• Water-dispersible granules.
• Excipient systems that maintain dose uniformity after opening.

The value proposition is operational as well as clinical. Caregivers need a product that is easy to measure, easy to administer, and stable after brief exposure to the environment.

Film-coating systems

A ready-to-use coating dispersion can reduce colorant variability, improve line efficiency, and standardize appearance across manufacturing sites. Coating suppliers can differentiate through lower coating weight, faster drying, improved moisture barrier performance, or compatibility with high-speed equipment.

Global supply and dual sourcing

Licensed generic manufacturers often operate under price pressure. Suppliers that can provide qualified manufacturing sites in multiple regions, regulatory support, and equivalent grades across sites can capture contracts that commodity excipient suppliers may lose.

What manufacturing and intellectual-property barriers affect excipient commercialization?

The principal barriers are regulatory comparability, process robustness, and freedom to operate.

An excipient supplier may face difficulty converting a technically attractive material into a commercial product if the generic manufacturer must repeat extensive development work or submit additional justification to regulators. Regulatory value rises when the supplier provides:

• Drug-master-file support where available.
• Compendial documentation.
• Nitrosamine and elemental-impurity assessments.
• Extractables and leachables data for packaging interactions.
• Stability data in relevant climatic zones.
• Change-notification commitments.
• Multiple manufacturing sites.
• Support for scale-up and process validation.

A new excipient or novel use of an excipient may also create patent opportunities. Potential claims could cover co-processed particles, particle-size distributions, granule structures, taste-masking systems, or manufacturing processes. Those claims must be drafted carefully because broad composition claims may face novelty and obviousness challenges, while narrow process claims may be difficult to enforce against suppliers using different equipment.

How does Epclusa compare with Mavyret from an excipient opportunity perspective?

Factor	Epclusa	Mavyret
Active ingredients	Sofosbuvir and velpatasvir	Glecaprevir and pibrentasvir
Main formulation challenge	Two-actives blend and velpatasvir dissolution	Multi-component dose and solubility management
Pediatric opportunity	Oral pellets and child-friendly administration	Pediatric granule/oral formulation opportunity
Generic-market driver	Licensing, broad HCV access, price competition	Broad treatment uptake and branded competition
Excipient differentiation	Blend uniformity, dissolution, pellets, coating	Solubility enhancement, dose uniformity, pediatric delivery
Biosimilar risk	None	None
Supply-chain priority	Dual sourcing and low-cost global supply	Same, with strong focus on complex formulation control

Epclusa is attractive for excipient suppliers because its fixed-dose combination requires more than a simple single-active tablet platform. Mavyret may offer greater opportunity for solubility-enhancing technologies, while Epclusa offers stronger opportunities in blend engineering, pediatric multiparticulates, and cost-efficient global manufacturing.

What is the revenue exposure and commercial outlook for Epclusa?

Epclusa remains commercially important because it is a broad-use HCV regimen and because Gilead has historically reported Epclusa as part of its HCV product portfolio. Public company reporting should be used to track product sales, geographic mix, licensing effects, and the impact of generic competition.[4]

The revenue outlook has four components:

1. High-income markets, where patent status and branded competition determine price.
2. Licensed markets, where volume can remain substantial despite low unit prices.
3. Public-health procurement, where supply reliability and total treatment cost dominate.
4. Pediatric and specialty presentations, where differentiated dosage forms can support higher margins.

For excipient companies, the addressable market is linked to the number of generic and licensed manufacturing sites rather than to the branded product’s peak sales alone. The most defensible opportunity is a formulation package that can be deployed across multiple manufacturers and countries without extensive reformulation.

Key Takeaways

• Epclusa is a sofosbuvir/velpatasvir fixed-dose combination available as tablets and pediatric oral pellets.
• Its listed excipients include copovidone, croscarmellose sodium, colloidal silicon dioxide, mannitol, microcrystalline cellulose, magnesium stearate, and conventional film-coating materials.
• The main generic formulation risks are blend segregation, dual-active dissolution control, moisture sensitivity, and pediatric administration.
• Excipient suppliers have the strongest opportunities in direct-compression systems, low-moisture grades, pediatric multiparticulates, film coatings, and dual-source supply.
• Epclusa has no biosimilar risk because it is a small-molecule drug.
• Generic-entry analysis must distinguish active-ingredient patents, fixed-dose combination patents, method-of-use claims, regulatory exclusivity, Paragraph IV filings, and settlement agreements.
• Licensed generic markets create volume opportunities even where margins are low.
• The FDA Orange Book, court records, FDA labeling, Gilead disclosures, and licensing databases should control current patent and launch-date assessments.

FAQs

Can an excipient change avoid Epclusa patent infringement?

It can reduce exposure to formulation claims, but it does not avoid patents covering sofosbuvir, velpatasvir, the fixed-dose combination, treatment methods, or manufacturing processes.

Is Epclusa a biologic that can face biosimilar competition?

No. Epclusa is a chemically synthesized small-molecule combination product and faces generic-drug competition rather than biosimilar competition.

Which excipient is most important for Epclusa tablet performance?

No single excipient controls performance. The most sensitive design variables are the interaction among the binder, diluents, superdisintegrant, lubricant, active particle properties, and compression process.

Are pediatric Epclusa pellets a stronger commercial opportunity than tablets?

They can be. Pediatric pellets address swallowing and administration barriers and offer greater differentiation than a conventional adult tablet, although they require stronger control of taste, dose uniformity, dust, packaging, and stability.

Can a generic Epclusa product use a different excipient system?

Yes. A different excipient system is generally permissible if the product satisfies applicable regulatory requirements, including quality, stability, dissolution, bioequivalence, labeling, and safety standards.

References

1. U.S. Food and Drug Administration. (2024). Epclusa prescribing information. Gilead Sciences, Inc.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Medicines Patent Pool. (n.d.). Hepatitis C licensing and access agreements.
4. Gilead Sciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.
6. International Council for Harmonisation. (2006). ICH Q9: Quality risk management.
7. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.